|
業務類別
|
Biotechnology |
|
業務概覽
|
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration(FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities toexpand the NITRICIL nitric oxide-based technology. |
| 公司地址
| 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703 |
| 電話號碼
| +1 919 908-2400 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pelthos.com |
| 員工數量
| 92 |
| Mr. Scott M. Plesha |
Chief Executive Officer, President and Director |
-- |
19/03/2026 |
| Mr. John M. Gay |
Chief Financial Officer, Treasurer and Secretary |
-- |
10/04/2026 |
| Mr. Sai Rangarao, M.B.A. |
Chief Commercial Officer |
-- |
19/03/2026 |
|
|
| Mr. Todd C. Davis |
Director |
19/03/2026 |
| Mr. Andrew J. Einhorn |
Independent Director |
19/03/2026 |
| Mr. Richard B. Baxter, M.B.A. |
Director |
19/03/2026 |
| Mr. Matthew Pauls, J.D.,M.B.A. |
Independent Director |
19/03/2026 |
| Mr. Peter S. Greenleaf |
Chairman of the Board |
19/03/2026 |
| Mr. Scott M. Plesha |
Chief Executive Officer, President and Director |
19/03/2026 |
| Mr. Ezra M. Friedberg |
Independent Director |
19/03/2026 |
| Dr. Richard Malamut |
Independent Director |
19/03/2026 |
|
|
|
|
